Clinical trial of iohexol in lumbar myelography.
Iohexol containing 180 mg I/ml was used in 20 patients for lumbar myelography. By using an adequate volume up to a maximum of 15 ml, satisfactory films were obtained in all cases. Minor or moderate adverse effects occurred in 4 patients. There were no changes in vital signs or neurologic examination related to the examinations. No patient had difficulty with concentration, personality changes or seizures. Later encephalographies performed in all patients before and during 24 h after the iohexol injections, showed no seizure or abnormal activity or any significant change. Repeated lumbar puncture was performed in 9 patients 24 h after the injection of iohexol. One of these, a patient with symptoms due to disc prolapse, whose CSF was abnormal before the myelography, had a slightly increased cellular response. There was no significant change in any of the other patients. Iohexol is a very satisfactory contrast medium for myelography and compared favorably with other non-ionic contrast media.
D000328:Adult; D000368:Aged; D001772:Blood Cell Count; D002555:Cerebrospinal Fluid / Q000032:analysis; D003287:Contrast Media / Q000009:adverse effects; D004341:Drug Evaluation; D006801:Humans; D007463:Iodobenzoates; D007472:Iohexol; D008161:Lumbosacral Region; D008297:Male; D008875:Middle Aged; D009192:Myelography / Q000379:methods*; D009325:Nausea / Q000139:chemically induced; D010523:Peripheral Nervous System Diseases / Q000139:chemically induced; D014283:Triiodobenzoic Acids / Q000009:adverse effects
D003287:Contrast Media; D007463:Iodobenzoates; D014283:Triiodobenzoic Acids; D007472:Iohexol